Grand Jean Capital Management Inc. Sells 127 Shares of Amgen Inc. (AMGN)
Grand Jean Capital Management Inc. reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,453 shares of the medical research company’s stock after selling 127 shares during the period. Grand Jean Capital Management Inc.’s holdings in Amgen were worth $402,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in AMGN. Kayne Anderson Rudnick Investment Management LLC raised its position in shares of Amgen by 12.8% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 31,108 shares of the medical research company’s stock worth $5,104,000 after buying an additional 3,532 shares during the last quarter. Blue Chip Partners Inc. raised its position in shares of Amgen by 8.3% in the first quarter. Blue Chip Partners Inc. now owns 21,462 shares of the medical research company’s stock worth $3,521,000 after buying an additional 1,652 shares during the last quarter. State of Tennessee Treasury Department raised its position in shares of Amgen by 51.4% in the first quarter. State of Tennessee Treasury Department now owns 783,570 shares of the medical research company’s stock worth $128,560,000 after buying an additional 265,931 shares during the last quarter. Zweig DiMenna Associates LLC purchased a new position in shares of Amgen during the first quarter worth approximately $410,000. Finally, Jaffetilchin Investment Partners LLC raised its position in shares of Amgen by 14.9% in the first quarter. Jaffetilchin Investment Partners LLC now owns 3,909 shares of the medical research company’s stock worth $641,000 after buying an additional 508 shares during the last quarter. Hedge funds and other institutional investors own 78.12% of the company’s stock.
Shares of Amgen Inc. (AMGN) traded down 0.201% during mid-day trading on Tuesday, reaching $171.435. The company had a trading volume of 250,188 shares. Amgen Inc. has a one year low of $133.64 and a one year high of $184.21. The firm has a market capitalization of $125.09 billion, a price-to-earnings ratio of 15.615 and a beta of 1.35. The stock has a 50 day moving average of $173.53 and a 200-day moving average of $168.31.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the previous year, the company earned $2.84 earnings per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. Equities analysts predict that Amgen Inc. will post $12.57 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be given a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.68%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s payout ratio is 41.93%.
Several research analysts have recently issued reports on AMGN shares. Cann restated a “buy” rating on shares of Amgen in a research report on Monday. Mizuho restated a “buy” rating and issued a $183.00 price target (down from $195.00) on shares of Amgen in a research report on Monday, August 21st. BidaskClub lowered Amgen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Argus raised their price target on Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. Finally, UBS AG set a $180.00 price target on Amgen and gave the stock a “hold” rating in a research report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $186.04.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.